Why the study?
What is the safety profile of disease-modifying agents used for the treatment of multiple sclerosis?
Population
Patients with multiple sclerosis (MS)
Design
Review
Authors
Loading...
Urges caution prescribing newer MS therapies amid safety data gaps; leaves open need for dedicated post-marketing surveillance studies.
What is the safety profile of disease-modifying agents used for the treatment of multiple sclerosis?
Newer MS therapies offer improved compliance but carry risks of severe adverse reactions, necessitating rigorous post-marketing surveillance.
Auricchio et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: